Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.
Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Geers D, Schmitz KS, Garcia Garrido HM, Koopmans MPG, Dalm VASH, Kootstra NA, Huckriede ALW, Lafeber M, van Baarle D, GeurtsvanKessel CH, de Vries RD, van der Kuy PHM; SWITCH Research Group. Sablerolles RSG, et al. Among authors: postma df. N Engl J Med. 2022 Mar 10;386(10):951-963. doi: 10.1056/NEJMoa2116747. Epub 2022 Jan 19. N Engl J Med. 2022. PMID: 35045226 Free PMC article. Clinical Trial.
Antibiotic treatment strategies for community-acquired pneumonia in adults.
Postma DF, van Werkhoven CH, van Elden LJ, Thijsen SF, Hoepelman AI, Kluytmans JA, Boersma WG, Compaijen CJ, van der Wall E, Prins JM, Oosterheert JJ, Bonten MJ; CAP-START Study Group. Postma DF, et al. N Engl J Med. 2015 Apr 2;372(14):1312-23. doi: 10.1056/NEJMoa1406330. N Engl J Med. 2015. PMID: 25830421 Free article. Clinical Trial.
Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol.
Sablerolles RSG, Goorhuis A, GeurtsvanKessel CH, de Vries RD, Huckriede ALW, Koopmans MPG, Lafeber M, Postma DF, van Baarle D, Visser LG, Dalm VASH, Kootstra NA, Rietdijk WJR, van der Kuy PHM. Sablerolles RSG, et al. Among authors: postma df. Front Immunol. 2021 Sep 24;12:753319. doi: 10.3389/fimmu.2021.753319. eCollection 2021. Front Immunol. 2021. PMID: 34691071 Free PMC article. No abstract available.
Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients.
Millat-Martinez P, Gharbharan A, Alemany A, Rokx C, Geurtsvankessel C, Papageorgiou G, van Geloven N, Jordans C, Groeneveld G, Swaneveld F, van der Schoot E, Corbacho-Monné M, Ouchi D, Piccolo Ferreira F, Malchair P, Videla S, García García V, Ruiz-Comellas A, Ramírez-Morros A, Rodriguez Codina J, Amado Simon R, Grifols JR, Blanco J, Blanco I, Ara J, Bassat Q, Clotet B, Baro B, Troxel A, Zwaginga JJ, Mitjà O, Rijnders BJA; CoV-Early study group; COnV-ert study group. Millat-Martinez P, et al. Nat Commun. 2022 May 11;13(1):2583. doi: 10.1038/s41467-022-29911-3. Nat Commun. 2022. PMID: 35546145 Free PMC article.
Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers.
Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Schmitz KS, Geers D, Bogers S, van Haren E, Koopmans MPG, Dalm VASH, Kootstra NA, Huckriede ALW, Akkerman R, Beukema M, Lafeber M, van Baarle D, de Vries RD, van der Kuy PHM, GeurtsvanKessel CH; SWITCH Research Group. Sablerolles RSG, et al. Among authors: postma df. Clin Infect Dis. 2023 Feb 8;76(3):e533-e536. doi: 10.1093/cid/ciac495. Clin Infect Dis. 2023. PMID: 35723273 Free PMC article.
Outpatient convalescent plasma therapy for high-risk patients with early COVID-19: a randomized placebo-controlled trial.
Gharbharan A, Jordans C, Zwaginga L, Papageorgiou G, van Geloven N, van Wijngaarden P, den Hollander J, Karim F, van Leeuwen-Segarceanu E, Soetekouw R, Lammers J, Postma D, Kampschreur L, Groeneveld G, Swaneveld F, van der Schoot CE, Götz H, Haagmans B, Koopmans M, Bogers S, Geurtsvankessel C, Zwaginga JJ, Rokx C, Rijnders B; CoV-Early study group. Gharbharan A, et al. Clin Microbiol Infect. 2023 Feb;29(2):208-214. doi: 10.1016/j.cmi.2022.08.005. Epub 2022 Aug 23. Clin Microbiol Infect. 2023. PMID: 36007870 Free PMC article. Clinical Trial.
Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination.
Geers D, Sablerolles RSG, van Baarle D, Kootstra NA, Rietdijk WJR, Schmitz KS, Gommers L, Bogers S, Nieuwkoop NJ, van Dijk LLA, van Haren E, Lafeber M, Dalm VASH, Goorhuis A, Postma DF, Visser LG, Huckriede ALW, Sette A, Grifoni A, de Swart RL, Koopmans MPG, van der Kuy PHM, GeurtsvanKessel CH, de Vries RD; SWITCH research group. Geers D, et al. Among authors: postma df. iScience. 2023 Jan 20;26(1):105753. doi: 10.1016/j.isci.2022.105753. Epub 2022 Dec 7. iScience. 2023. PMID: 36507223 Free PMC article.
Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocol.
Tan NH, Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Bogers S, Geers D, Zaeck LM, Koopmans MPG, Dalm VASH, Kootstra NA, Huckriede ALW, van Baarle D, Lafeber M, GeurtsvanKessel CH, de Vries RD, van der Kuy PM. Tan NH, et al. Among authors: postma df. Front Immunol. 2022 Nov 29;13:1067749. doi: 10.3389/fimmu.2022.1067749. eCollection 2022. Front Immunol. 2022. PMID: 36524126 Free PMC article.
Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.
Tan NH, Geers D, Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Bogers S, van Dijk LLA, Gommers L, van Leeuwen LPM, Boerma A, Nijhof SH, van Dort KA, Koopmans MPG, Dalm VASH, Lafeber M, Kootstra NA, Huckriede ALW, van Baarle D, Zaeck LM, GeurtsvanKessel CH, de Vries RD, van der Kuy PHM; SWITCH ON Research Group. Tan NH, et al. Among authors: postma df. Lancet Infect Dis. 2023 Aug;23(8):901-913. doi: 10.1016/S1473-3099(23)00140-8. Epub 2023 Apr 21. Lancet Infect Dis. 2023. PMID: 37088096 Free PMC article. Clinical Trial.
Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters.
Zaeck LM, Tan NH, Rietdijk WJR, Geers D, Sablerolles RSG, Bogers S, van Dijk LLA, Gommers L, van Leeuwen LPM, Rugebregt S, Goorhuis A, Postma DF, Visser LG, Dalm VASH, Lafeber M, Kootstra NA, Huckriede ALW, Haagmans BL, van Baarle D, Koopmans MPG; SWITCH-ON Research Group; van der Kuy PHM, GeurtsvanKessel CH, de Vries RD. Zaeck LM, et al. Among authors: postma df. Nat Commun. 2024 May 18;15(1):4224. doi: 10.1038/s41467-024-48414-x. Nat Commun. 2024. PMID: 38762522 Free PMC article. Clinical Trial.
62 results